Lupuzor, a non-immunosuppressant therapy for lupus created by Dr. Sylviane Muller’s team at the CNRS Immunopathologie et Chimie Thérapeutique laboratory, is progressing to a Phase 3 clinical trial, the last stage before possible market approval. Several American and European physicians and investigators recently gathered in Paris to discuss the launch of…
The division of Nephrology and Hypertension at the Texas Tech University Health Science Center (TTUHSC) El Paso has been invited to collaborate in a multiple-institute, nationwide research consortium that aims to better understand the causes behind, and discover new potential treatments for, lupus nephritis. Systemic lupus erythematosus (SLE) is a chronic autoimmune disease,…
Researchers have identified increased exosomal microRNAs in lupus nephritis patients’ urine, and think it may prove to be a useful, non-invasive disease biomarker. Their paper, titled “Increased Urinary Exosomal MicroRNAs in Patients with Systemic Lupus Erythematosus,” was published in PLOS One. Systemic lupus erythematosus (SLE), a chronic autoimmune disease,…
Horizon Pharma announced a partnership with the Alliance for Lupus Research (ALR), a non-governmental national health organization, to study the efficacy and safety of RAYOS (prednisone) delayed-release tablets to manage systemic lupus erythematosus (SLE) therapy. RAYOS, known as LODOTRA in Europe, differs from other prednisone formulations because the pharmacokinetic properties of its formulation allow the delayed…
GlaxoSmithKline (GSK) announced positive results from its BLISS-SC Phase 3 study testing the efficacy of Benlysta (belimumab) in patients with active and autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy. The results, detailed in “A Randomized, Double-Blind, Placebo-Controlled, 52-Week Study of the Efficacy and Safety of Belimumab Administered Subcutaneously Plus Standard…
Mallinckrodt Pharmaceuticals has revealed that H.P. Acthar Gel is effective in the treatment of patients with persistently active systemic lupus erythematosus (SLE) who are under corticosteroid therapy, according to recent study results. Though the study’s primary endpoint was not met, the drug led to attenuation of disease activity in participants and met some…
According to a recent study, complement activation is associated with an increased risk of pregnancy complications in patients with systemic lupus erythematosus (SLE) and antiphospholipid antibodies (APL) syndrome. The study is part of PROMISSE (Predicators of pRegnacy Outcome: BioMarkers in antiphospholipid antibody Syndrome and System lupus Erythematosus) — a research effort…
Researchers from Emory University School of Medicine have identified and defined a set of autoantibody-producing cells responsible for the autoimmunity profiles observed in lupus erythematosus patients. The research paper, entitled “Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus” was published in Nature…
Researchers at the UT Southwestern Medical center in Dallas, TX have discovered that activating a specific enzyme, cGAS, can sound an alarm for the body’s innate immune system, leading to the development of Aicardi-Goutieres Syndrome (AGS) and systemic lupus erythematosus (SLE) in mice while inhibiting this enzyme leads to their rescue. The research paper,…
Transplanted mesenchymal stem cells that can differentiate into several types of cells are known to be beneficial in treating symptoms of lupus disease, though researchers were at a loss as to why. Now, scientists at the University of Pennsylvania, working with collaborators, have shed light on the mechanisms of bone protection provided by this therapy,…